Page title
Search SAMHSA Publications and Digital Products
Store Facets Summary
- Clear all filters
- Remove Professional Care Providers
- Remove Family & Advocates
- Remove Substance Abuse
- Remove People with Substance Use or Abuse Problems as Population Group
- Remove Practitioner/Professional
- Remove Opioids or Opiates
- Remove Prescription Drugs
- Remove Medication-Assisted Treatment
- Remove Referral to Treatment
Main page content
Displaying results 1 - 5 of 5
TIP 63: Medications for Opioid Use Disorder - Executive Summary
Published: August 2021
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
TIP 63: Medications for Opioid Use Disorder - Full Document
Published: July 2021
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Use of Medication-Assisted Treatment in Emergency Departments
Published: January 2021
This guide examines emerging and best practices for initiating medication-assisted treatment in emergency departments. It also reviews the existing literature and science of the topic, identifies gaps in knowledge, and discusses challenges of implementation.
Employee Assistance Program (EAP) Prescription Drug Toolkit and Fact Sheets
Published: January 2021
The EAP Prescription Drug Toolkit and Fact Sheets provide guidance related to counseling, referrals, and follow-up services (e.g., alternatives to prescription drugs, workplace drug misuse and relapse prevention, dangers of combined drug use, screenings, and evaluations before returning to work).
Advisory: Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update
Published: March 2016
This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.